Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Katrina Sweeney"'
Autor:
Gunnel Halldén, Katrina Sweeney
Publikováno v:
Oncolytic Virotherapy
Prostate cancer is a leading cause of cancer-related death and morbidity in men in the Western world. Tumor progression is dependent on functioning androgen receptor signaling, and initial administration of antiandrogens and hormone therapy (androgen
Autor:
Colleen C. Nelson, Katrina Sweeney, Meenakshi Malhotra, Brett G. Hollier, Raphael Darcy, Caitriona M. O'Driscoll, James C. Evans
Publikováno v:
International journal of pharmaceutics. 532(1)
The main barrier to the development of an effective RNA interference (RNAi) therapy is the lack of a suitable delivery vector. Modified cyclodextrins have emerged in recent years for the delivery of siRNA. In the present study, a folate-targeted amph
Autor:
Sarah P. Blagden, Sadaf Ghaem-Maghami, Andrea J. Berman, Normala Abd-Latip, Roni M. Lahr, Jennifer H. Steel, Hiba A. Al-Ashtal, Justin Weir, Eric O. Aboagye, Manuela Mura, Mona El-Bahrawy, Haonan Lu, T.G. Hopkins, Katrina Sweeney
Publikováno v:
Nucleic Acids Research
RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated expression of the protein in hepatocellular and lung cancers is correlated with
Autor:
Philip A. Gregory, Margaret M. Centenera, Lisa M. Butler, Brett G. Hollier, Rajdeep Das, Nataly Stylianou, Wayne D. Tilley, Scott L. Townley, Adrienne R. Hanson, Amina Zoubeidi, Gregory J. Goodall, Carolina Soekmadji, Katrina Sweeney, Colleen C. Nelson, Isabel Coutinho, Lidija Jovanovic, Luke A. Selth
Publikováno v:
Europe PubMed Central
MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely corre
Autor:
Daniel Öberg, Enrique Miranda, Nicholas R. Lemoine, Gunnel Halldén, Katrina Sweeney, Derek Davies, Stephan Leitner
Publikováno v:
Clinical Cancer Research. 15:1730-1740
Purpose: Pancreatic adenocarcinoma is a rapidly progressive malignancy that is highly resistant to current chemotherapeutic modalities and almost uniformly fatal. We show that a novel targeting strategy combining oncolytic adenoviral mutants with the
Autor:
Elizabeth D. Williams, Nataly Stylianou, Katrina Sweeney, Colleen C. Nelson, Qiuhua Hu, Brett G. Hollier, Ellca Ratther, Gregor Tevz
Publikováno v:
Cancer Research. 77:818-818
Recent evidence suggests that the use of potent androgen receptor (AR) antagonists have contributed to the increased prevalence of prostate cancer (PCa) tumors exhibiting therapy resistance. Androgen targeted therapies (ATT) inhibit the androgen/AR a
Autor:
Gregor Tevz, Atefeh Taherianfard, Melanie Lehman, Elizabeth D. Williams, Ellca Ratther, Nataly Stylianou, Jennifer H. Gunter, Katrina Sweeney, Martin E. Gleave, Colleen C. Nelson, Brett G. Hollier, Akanksha Upadhyaya, Katrina J Pirlo
Publikováno v:
Cancer Research. 77:4909-4909
Reactivation of the embryonic developmental pathway, epithelial-to-mesenchymal transition (EMT) is associated with prostate cancer (PCa) metastasis and therapy resistance. Recent evidence has demonstrated EMT is stimulated following androgen targeted
Autor:
Brian W.C. Tse, Colleen C. Nelson, Brett G. Hollier, Katrina Sweeney, Elizabeth D. Williams, Ellca Ratther, Pamela J. Russell, Qiuhua Hu
Publikováno v:
Cancer Research. 77:2855-2855
Introduction Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Initially, PCa growth and progression is primarily driven by androgen stimulation of the androgen receptor (AR). As such, the standard treatments for PCa t
Autor:
T.G. Hopkins, Sadaf Ghaem-Maghami, Justin Weir, N. Abd-Latip, Manuela Mura, Sarah P. Blagden, G. Gabra, Katrina Sweeney
Publikováno v:
European Journal of Cancer. 50:S26
Publikováno v:
Cancer Research. 72:2712-2712
Androgen receptor (AR) signalling is active in most hormone-refractory prostate cancers (PCa) and suppression of its activity impedes cell proliferation. We demonstrate that Hey1, a co-repressor of AR, is a potential therapeutic transgene for treatme